Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance. (Q51051494)

27 March 2018

title

Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance. (English)

1 reference

27 March 2018

1 reference

Taro Ohba

1

1 reference

27 March 2018

Gouji Toyokawa

2

1 reference

27 March 2018

Takuro Kometani

3

1 reference

27 March 2018

Kaname Nosaki

4

1 reference

27 March 2018

Fumihiko Hirai

5

1 reference

27 March 2018

Masafumi Yamaguchi

6

1 reference

27 March 2018

Motoharu Hamatake

7

1 reference

27 March 2018

Takashi Seto

8

1 reference

27 March 2018

Yukito Ichinose

9

1 reference

27 March 2018

Kenji Sugio

10

1 reference

27 March 2018

publication date

23 April 2013

1 reference

27 March 2018

published in

Surgery Today

1 reference

27 March 2018

volume

44

1 reference

27 March 2018

page(s)

478-486

1 reference

27 March 2018

issue

3

1 reference

27 March 2018

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

EGFR and erbB2 mutation status in Japanese lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0589-2

ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis

21 January 2018

1 reference

12 December 2020

K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas

1 reference

12 December 2020

Clinicopathological features of lung adenocarcinoma with KRAS mutations

1 reference

12 December 2020

A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice

1 reference

12 December 2020

Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype

1 reference

12 December 2020

The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma

1 reference

12 December 2020

K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung

1 reference

12 December 2020

Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

1 reference

12 December 2020

10.1007/S00595-013-0589-2

Identifiers

DOI

1 reference

27 March 2018

PubMed ID

23609009

1 reference

27 March 2018